Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2<i>S</i>)-4-(2,5-Difluorophenyl)-<i>N</i>-[(3<i>R</i>,4<i>S</i>)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-<i>N</i>-methyl-2-phenyl-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory CancerChristopher D. Cox, George D. Hartman, Marc Abrams et al.|Journal of Medicinal Chemistry|2008Cited by 156
Development of thioquinazolinones, allosteric Chk1 kinase inhibitorsAntonella Converso, George D. Hartman, Timothy J. Hartingh et al.|Bioorganic & Medicinal Chemistry Letters|2008Cited by 74
Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSPMark E. Fraley, George D. Hartman, R. M. Garbaccio et al.|Bioorganic & Medicinal Chemistry Letters|2006Cited by 64
Kinesin spindle protein (KSP) inhibitors. Part V: Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoproteinChristopher D. Cox, George D. Hartman, Michael J. Breslin et al.|Bioorganic & Medicinal Chemistry Letters|2007Cited by 53
Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubilityR. M. Garbaccio, George D. Hartman, Mark E. Fraley et al.|Bioorganic & Medicinal Chemistry Letters|2006Cited by 47